Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Sarcoma 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 4Neoplasms 3Virus Diseases 1Urinary Bladder Neoplasms 1Sarcoma 1Multiple Myeloma 1Melanoma 1Lymphoma 1Kidney Neoplasms 1Gastrointestinal Cancer Metastatic 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1Breast Neoplasms 1Adenoviridae Infections 1

Interventions

pembrolizumab 28Docetaxel 21Gemcitabine 19Nivolumab 15Paclitaxel 13Prednisone 12Leuprolide 11pazopanib 10Radiotherapy 10Cisplatin 10Sunitinib 9Sorafenib 9Ipilimumab 8Blood Specimen Collection 8Bevacizumab 8avelumab 7atezolizumab 7Therapeutics 7Thalidomide 7Cyclophosphamide 7Carboplatin 7Standard of Care 6Radiation 6Mitomycin 6Interleukin-2 6Cetuximab 6Axitinib 6padeliporfin 5enzalutamide 5cemiplimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × Interferons × Genitourinary × Clear all
NCT01438112 2021-04-14

BOND

CG Oncology, Inc.

Phase 2/3 Terminated
22 enrolled
Genitourinary

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

NCT00352859 2014-12-30

Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib

Bayer

Phase 4 Terminated
2 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasms

NCT00117637 2014-10-31

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

Bayer

Phase 2 Completed
189 enrolled 44 charts
Genitourinary

Carcinoma, Renal Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡